Dimensional Fund Advisors LP Purchases 320,724 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Dimensional Fund Advisors LP boosted its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 18.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,035,070 shares of the specialty pharmaceutical company's stock after purchasing an additional 320,724 shares during the period. Dimensional Fund Advisors LP owned about 3.37% of Jazz Pharmaceuticals worth $250,619,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. IFP Advisors Inc bought a new position in shares of Jazz Pharmaceuticals during the fourth quarter valued at $25,000. Quadrant Capital Group LLC raised its stake in shares of Jazz Pharmaceuticals by 97.1% during the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock valued at $25,000 after acquiring an additional 101 shares during the last quarter. CoreFirst Bank & Trust bought a new position in shares of Jazz Pharmaceuticals during the fourth quarter valued at $28,000. Allianz SE bought a new position in shares of Jazz Pharmaceuticals during the fourth quarter valued at $29,000. Finally, Jones Financial Companies Lllp raised its stake in shares of Jazz Pharmaceuticals by 75.1% during the fourth quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company's stock valued at $37,000 after acquiring an additional 130 shares during the last quarter. Institutional investors own 89.14% of the company's stock.

Jazz Pharmaceuticals Stock Up 1.7 %

Shares of Jazz Pharmaceuticals stock traded up $1.82 on Friday, hitting $110.80. The company had a trading volume of 896,340 shares, compared to its average volume of 798,495. The stock has a market capitalization of $6.73 billion, a price-to-earnings ratio of 15.61, a P/E/G ratio of 1.04 and a beta of 0.42. Jazz Pharmaceuticals plc has a 1 year low of $95.49 and a 1 year high of $148.06. The stock has a 50 day moving average of $124.64 and a 200-day moving average of $122.41. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on JAZZ shares. HC Wainwright lifted their target price on shares of Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a "buy" rating in a research note on Monday, March 10th. Wells Fargo & Company raised shares of Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and lifted their target price for the stock from $130.00 to $170.00 in a research note on Thursday, February 13th. Barclays reissued an "overweight" rating and set a $200.00 target price (up previously from $190.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, February 27th. Morgan Stanley reissued an "overweight" rating and set a $183.00 target price (up previously from $175.00) on shares of Jazz Pharmaceuticals in a research note on Friday, March 7th. Finally, UBS Group raised Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and boosted their target price for the company from $145.00 to $179.00 in a research report on Friday, March 7th. One equities research analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $187.71.

Insider Transactions at Jazz Pharmaceuticals

In related news, CAO Patricia Carr sold 1,140 shares of the stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $137.81, for a total transaction of $157,103.40. Following the completion of the sale, the chief accounting officer now directly owns 7,012 shares of the company's stock, valued at approximately $966,323.72. This trade represents a 13.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $122.31, for a total value of $183,465.00. Following the sale, the chief executive officer now directly owns 439,744 shares of the company's stock, valued at $53,785,088.64. The trade was a 0.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 28,736 shares of company stock valued at $4,023,305 over the last ninety days. 4.20% of the stock is currently owned by insiders.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.